10 results on '"Jin, Moonsoo M."'
Search Results
2. Transposition into Replicating DNA Occurs through Interaction with the Processivity Factor
- Author
-
Parks, Adam R., Li, Zaoping, Shi, Qiaojuan, Owens, Roisin M., Jin, Moonsoo M., and Peters, Joseph E.
- Subjects
Machinery ,Magneto-electric machines ,DNA replication ,Proteins ,Transposons ,Biological sciences - Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.cell.2009.06.011 Byline: Adam R. Parks (1), Zaoping Li (1), Qiaojuan Shi (1), Roisin M. Owens (2), Moonsoo M. Jin (2), Joseph E. Peters (1) Keywords: DNA; PROTEINS; MICROBIO Abstract: The bacterial transposon Tn7 directs transposition into actively replicating DNA by a mechanism involving the transposon-encoded protein TnsE. Here we show that TnsE physically and functionally interacts with the processivity factor of the DNA replication machinery in vivo and in vitro. Our work establishes an in vitro TnsABC+E transposition reaction reconstituted from purified proteins and target DNA structures. Using the in vitro reaction we confirm that the processivity factor specifically reorders TnsE-mediated transposition events on target DNAs in a way that matches the bias with active DNA replication in vivo. The TnsE interaction with an essential and conserved component of the replication machinery, and a DNA structure reveals a mechanism by which Tn7, and probably other elements, selects target sites associated with DNA replication. Author Affiliation: (1) Department of Microbiology, Cornell University, Ithaca, NY 14853, USA (2) Department of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA Article History: Received 28 April 2008; Revised 23 March 2009; Accepted 1 June 2009 Article Note: (miscellaneous) Published: August 20, 2009
- Published
- 2009
3. [18F]RPS-544: A PET tracer for imaging the chemokine receptor CXCR4.
- Author
-
Amor-Coarasa, Alejandro, Kelly, James, Ponnala, Shashikanth, Vedvyas, Yogindra, Nikolopoulou, Anastasia, Jr.Williams, Clarence, Jin, Moonsoo M., David Warren, J., and Babich, John W.
- Subjects
- *
CHEMOKINE receptors , *RADIOACTIVE tracers , *POSITRON emission tomography , *GENE expression , *PHARMACOLOGY - Abstract
Introduction CXCR4 specific [ 18 F]-labeled positron emission tomography (PET) imaging agents are needed which would enable general distribution of the radiotracer for clinical investigation. We sought to synthesize, radiolabel and evaluate [ 18 F]RPS-544, a novel non-peptide CXCR4 antagonist as a CXCR4 specific probe. We compared [ 18 F]RPS-544 with the previously published [ 18 F]-3 ([ 18 F]RPS-510 in this paper) in a bi-lateral tumor model of differential CXCR4 expression for its ability to selectively target CXCR4 expression. Methods Radiolabeling of [ 18 F]RPS-544 and [ 18 F]RPS-510 was performed by aromatic substitution on a 6-nitropyridyl group using no-carrier-added [ 18 F]fluoride under basic conditions. 18 F incorporation was determined by radioHPLC. Semi-preparative HPLC was used to purify the final product prior to reformulation. Imaging and biodistribution was performed in nude mice with bilateral PC3 (CXCR4+ and WT) xenograft tumors at 1, 2 and 4 h post injection. Results RPS-544 bound CXCR4 with an IC50 of 4.9 ± 0.3 nM. [ 18 F]RPS-544 showed preferential uptake in CXCR4+ tumors, with a CXCR4/WT ratio of 3.3 ± 1.3 at 1 h p.i. and 2.3 ± 0.5 at 2 h p.i. Maximum uptake in the CXCR4+ tumors was 3.4 ± 1.2%ID/g at 1 h p.i., significantly greater (p = 0.003) than the uptake in the WT tumor. Tumor/blood ratios were 2.5 ± 0.4 and 3.6 ± 0.3 at 1 and 2 h p.i. Tumor/muscle ratios were >4 at all time-points. Tumor/lung ratios were >2 at 1 h and 2 h p.i. Substantial uptake was observed in the liver (15–25%ID/g), kidneys (25–35%ID/g), the small intestine (1–7%ID/g) and the large intestine (1–12%ID/g). Blood concentrations varied over time (0.5–2%ID/g). All other organs showed uptake of <1%ID/g at all time points studied with clearance profiles similar to blood clearance. Conclusions Here we present, to the best of our knowledge, the first high affinity [18F]-labeled tracer, suitable for in vivo PET imaging of CXCR4. [18F]RPS-544 displayed high affinity for CXCR4 and good tumor uptake with a maximum uptake at 1 h p.i.. CXCR4 dependent uptake was demonstrated using bilateral tumors with differential CXCR4 expression as well as pharmacological blockade using the known CXCR4 antagonist, AMD-3100. Tissue contrast as judged by tumor to normal tissue ratios was positive in several key tissues. The structural and pharmacological similarities between [18F]RPS-544 and the approved drug AMD-3465, combined with the ease of synthesis and high molar activity (>185 GBq/μmol) achieved during radiosynthesis could lead to accelerated translation into the clinic. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
4. Tumor suppression via paclitaxel-loaded drug carriers that target inflammation marker upregulated in tumor vasculature and macrophages
- Author
-
Park, Spencer, Kang, Sungkwon, Chen, Xiaoyue, Kim, Esther J., Kim, Jeeyoung, Kim, Nahae, Kim, Juyoung, and Jin, Moonsoo M.
- Subjects
- *
TUMOR suppressor genes , *PACLITAXEL , *DRUG carriers , *TARGETED drug delivery , *INFLAMMATION , *GENETIC markers , *GENETIC regulation , *MACROPHAGES , *NANOMEDICINE - Abstract
Abstract: Clinically approved chemotherapeutic nanoparticles may provide advantages over free drugs by achieving slower clearance and preferential accumulation in tumors. However, the lack of leaky vasculatures can create barriers to the permeation of ∼100nm-sized nanoparticles in solid tumors. We hypothesized that nanoparticles designed to target both tumor and tumor stroma would penetrate deeper into the tumors. To construct such comprehensive drug carriers, we utilized cross-linked amphiphilic polymer nanoparticles and functionalized them to target ICAM-1, a biomarker prevalent in various tumors and inflamed tumor stroma. The targeting moiety was derived from the modular domain present in αL integrin, which was engineered for high affinity and cross-reactivity with human and murine ICAM-1. ICAM-1-selective delivery of paclitaxel produced potent tumor suppression of not only ICAM-1-positive cervical cancer cells but also ICAM-1-negative tumors, presumably by causing cytotoxicity in tumor-associated endothelium (CD31+) and macrophages (CD68+) over-expressing ICAM-1. Contrary to the strategies of targeting only the tumor or specific tumor stromal constituents, we present a strategy in delivering therapeutics to the major cellular components of solid tumors. Drug carriers against inflammation-biomarkers may be effective against many different types of tumors, while being less susceptible to the highly mutable nature of tumor markers. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
5. Inflamed leukocyte-mimetic nanoparticles for molecular imaging of inflammation
- Author
-
Chen, Xiaoyue, Wong, Richard, Khalidov, Ildar, Wang, Andrew Y., Leelawattanachai, Jeerapond, Wang, Yi, and Jin, Moonsoo M.
- Subjects
- *
LEUCOCYTES , *NANOPARTICLES , *INFLAMMATION , *INTEGRINS , *MAGNETIC resonance imaging , *TREATMENT of neurodegeneration , *CARDIOVASCULAR disease diagnosis , *ENDOTHELIUM - Abstract
Abstract: Dysregulated host inflammatory response causes many diseases, including cardiovascular and neurodegenerative diseases, cancer, and sepsis. Sensitive detection of the site of inflammation will, therefore, produce a wide-ranging impact on disease diagnosis and treatment. We hypothesized that nanoprobes designed to mimic the molecular interactions occurring between inflamed leukocytes and endothelium may possess selectivity toward diverse host inflammatory responses. To incorporate inflammation-sensitive molecular interactions, super paramagnetic iron oxide nanoparticles were conjugated with integrin lymphocyte function-associated antigen (LFA)-1 I domain, engineered to mimic activated leukocytes in physiology. Whole body optical and magnetic resonance imaging in vivo revealed that leukocyte-mimetic nanoparticles localized preferentially to the vasculature within and in the invasive front of the tumor, as well as to the site of acute inflammation. This study explored in vivo detection of tumor-associated vasculature with systemically injected inflammation-specific nanoparticles, presenting a possibility of tumor detection by inflamed tumor microenvironment. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
6. Tunable physiologic interactions of adhesion molecules for inflamed cell-selective drug delivery
- Author
-
Kang, Sungkwon, Park, Taehyun, Chen, Xiaoyue, Dickens, Greg, Lee, Brian, Lu, Kevin, Rakhilin, Nikolai, Daniel, Susan, and Jin, Moonsoo M.
- Subjects
- *
PROTEIN-protein interactions , *CELL adhesion molecules , *INFLAMMATION , *DRUG delivery systems , *ANTI-inflammatory agents , *DRUG administration , *GENE expression , *POLYSACCHARIDES , *INTEGRINS - Abstract
Abstract: Dysregulated inflammation contributes to the pathogenesis of various diseases. Therapeutic efficacy of anti-inflammatory agents, however, falls short against resilient inflammatory responses, whereas long-term and high-dose systemic administration can cause adverse side effects. Site-directed drug delivery systems would thus render more effective and safer treatments by increasing local dosage and minimizing toxicity. Nonetheless, achieving clinically effective targeted delivery to inflammatory sites has been difficult due to diverse cellular players involved in immunity and endogenous targets being expressed at basal levels. Here we exploit a physiological molecular interaction between intercellular adhesion molecule (ICAM)-1 and lymphocyte function associated antigen (LFA)-1 to deliver a potent anti-inflammatory drug, celastrol, specifically and comprehensively to inflamed cells. We found that affinity and avidity adjusted inserted (I) domain, the major binding site of LFA-1, on liposome surface enhanced the specificity toward lipopolysaccharides (LPS)-treated or inflamed endothelial cells (HMEC-1) and monocytes (THP-1) via ICAM-1 overexpression, reflecting inherent affinity and avidity modulation of these molecules in physiology. Targeted delivery of celastrol protected cells from recurring LPS challenges, suppressing pro-inflammatory responses and inflammation-induced cell proliferation. Targeted delivery also blocked THP-1 adhesion to inflamed HMEC-1, forming barriers to immune cell accumulation and to aggravating inflammatory signals. Our results demonstrate affinity and avidity of targeting moieties on nanoparticles as important design parameters to ensure specificity and avoid toxicities. We anticipate that such tunable physiologic interactions could be used for designing effective drug carriers for in vivo applications and contribute to treating a range of immune and inflammatory diseases. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
7. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases
- Author
-
Tremblay, Jacqueline M., Kuo, Chueh-Ling, Abeijon, Claudia, Sepulveda, Jorge, Oyler, George, Hu, Xuebo, Jin, Moonsoo M., and Shoemaker, Charles B.
- Subjects
- *
BOTULINUM toxin , *NEUROTOXIC agents , *IMMUNOGLOBULINS , *CLOSTRIDIUM botulinum , *PROTEASE inhibitors , *CYTOMEGALOVIRUSES , *GREEN fluorescent protein , *METALLOPROTEINASES , *GLUTATHIONE transferase - Abstract
Abstract: Botulinum neurotoxins (BoNTs) function by delivering a protease to neuronal cells that cleave SNARE proteins and inactivate neurotransmitter exocytosis. Small (14 kDa) binding domains specific for the protease of BoNT serotypes A or B were selected from libraries of heavy chain only antibody domains (VHHs or nanobodies) cloned from immunized alpacas. Several VHHs bind the BoNT proteases with high affinity (K D near 1 nM) and include potent inhibitors of BoNT/A protease activity (K i near 1 nM). The VHHs retain their binding specificity and inhibitory functions when expressed within mammalian neuronal cells as intrabodies. A VHH inhibitor of BoNT/A protease was able to protect neuronal cell SNAP25 protein from cleavage following intoxication with BoNT/A holotoxin. These results demonstrate that VHH domains have potential as components of therapeutic agents for reversal of botulism intoxication. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
8. Self-assembled nanoplatform for targeted delivery of chemotherapy agents via affinity-regulated molecular interactions
- Author
-
Park, Spencer, Kang, Sungkwon, Veach, Alexander J., Vedvyas, Yogindra, Zarnegar, Rasa, Kim, Ju-Young, and Jin, Moonsoo M.
- Subjects
- *
MOLECULAR self-assembly , *TARGETED drug delivery , *DRUG delivery systems , *CANCER chemotherapy , *NANOPARTICLES , *URETHANE , *CELL adhesion molecules - Abstract
Abstract: Site-specific delivery of drugs while minimizing unwanted distribution has been one of the pursued goals in cancer therapy. In this endeavor, we have developed targeted polymeric nanoparticles called amphiphilic urethane acrylate nonionomer (UAN) for encapsulation of diverse water-insoluble drugs and diagnostic agents, as well as for simple and reproducible surface conjugation of targeting ligands. Using monoclonal antibodies or lymphocyte function-associated antigen-1 (LFA-1) I domain engineered for varying affinities to intercellular adhesion molecule (ICAM)-1, we were able to deliver UAN nanoparticles to human cancer cells with the efficiency dependent on the strength of the molecular interactions and the degree of ICAM-1 expression on cell surface. Compared to non-specific uptake of free drugs, targeted delivery of UAN nanoparticles carrying equal amount of drugs produced more potent cytotoxicity. Notably, without the targeting ligands attached, UAN nanoparticles were largely precluded from non-specific uptake by the cells, resulting in much lower toxicity. The versatility of our UAN nanoparticles in both payload encapsulation and presentation of targeting ligands may facilitate developing a robust platform for evaluating various combinations of cancer drugs and molecular interactions toward developing effective cancer therapy formulations. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
9. Engineering of Single Ig Superfamily Domain of Intercellular Adhesion Molecule 1 (ICAM-1) for Native Fold and Function.
- Author
-
Owens, Róisin M., Xiaoling Gu, Shin, Miran, Springer, Timothy A., and Jin, Moonsoo M.
- Subjects
- *
IMMUNOGLOBULINS , *CELL membranes , *BINDING sites , *INTEGRINS , *LYMPHOCYTES , *CELL adhesion molecules , *ANTIGENS - Abstract
The immunoglobulin (Ig) superfamily is one of the largest families in the vertebrate genome, found most frequently in cell surface molecules. Intercellular adhesion molecule-1 (ICAM-1) contains five extracellular Ig superfamily domains (D1-D5) of which the first domain, D1, is the binding site for the integrin lymphocyte function-associated antigen-1 (LFA-1) and human rhinovirus. Despite the modular nature of many Ig superfamily domains with respect to domain folding and ligand recognition, D1 does not fold on its own due to the loss of its interaction with the second domain. The goal of this study was to engineer ICAM-1 D1 by introducing mutations that would stabilize the Ig superfamily domain fold while retaining its ability to bind to LFA-1 and rhinovirus. First, with a directed evolution approach, we isolated mutations in D1 that showed binding to conformation-specific antibodies and the ligand binding domain of LFA-1 called the inserted, or I, domain. Then, with a rational design approach we introduced mutations that contributed to the stability of ICAM-1 D1 in solution. The mutations that restored native folding of D1 in isolation were those that would convert hydrogen bond networks in buried regions into hydrophobic contacts. Notably, for most mutations, identical or similar types of substitutions were found in ICAM-1 molecules of different species and other ICAM family members. The systematic approach demonstrated in this study to engineer a single Ig superfamily fold in ICAM-1 can be broadly applicable to the engineering of modular Ig superfamily domains in other cell surface molecules. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
10. Yeast Surface Two-hybrid for Quantitative in Vivo Detection of Protein-Protein Interactions via the Secretory Pathway.
- Author
-
Hu, Xuebo, Kang, Sungkwon, Chen, Xiaoyue, Shoemakers, Charles B., and Jin, Moonsoo M.
- Subjects
- *
PROTEIN-protein interactions , *YEAST research , *CELL membranes , *EPITOPES , *PLASMONS (Physics) , *INTEGRINS , *BOTULINUM toxin - Abstract
A quantitative in vivo method for detecting protein-protein interactions will enhance our understanding of protein interaction networks and facilitate affinity maturation as well as designing new interaction pairs. We have developed a novel platform, dubbed "yeast surface two-hybrid (YS2H)," to enable a quantitative measurement of pairwise protein interactions via the secretory pathway by expressing one protein (bait) anchored to the cell wall and the other (prey) in soluble form. In YS2H, the prey is released either outside of the cells or remains on the cell surface by virtue of its binding to the bait. The strength of their interaction is measured by antibody binding to the epitope tag appended to the prey or direct readout of split green fluorescence protein (GFP) complementation. When two a-helices forming coiled coils were expressed as a pair of prey and bait, the amount of the prey in complex with the bait progressively decreased as the affinity changes from 100 μM to 10 μM. With GFP complementation assay, we were able to discriminate a 6-log difference in binding affinities in the range of 100 pM to 100 μM. The affinity estimated from the level of antibody binding to fusion tags was in good agreement with that measured in solution using a surface plasmon resonance technique. In contrast, the level of GFP complementation linearly increased with the on rate of coiled coil interactions, likely because of the irreversible nature of GFP reconstitution. Furthermore, we demonstrate the use of YS2H in exploring the nature of antigen recognition by antibodies and activation allostery in integrins and in isolating heavy chainonly antibodies against botulinum neurotoxin. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.